RheaVita has become a formal member of LyoHUB, the Advanced Lyophilization Technology Hub, which aims to advance the science and technology of freeze-drying (lyophilization). LyoHUB's mission includes identifying and disseminating best practices for lyophilization equipment performance, testing, and validation, as well as conducting applied research to advance lyophilization processes and products.

As a pioneer in controlled, continuous freeze-drying technology for biopharmaceuticals, RheaVita's membership aligns with LyoHUB's objectives. RheaVita's patented continuous freeze-drying technology integrates all traditional freeze-drying steps into a continuous production line, enabling rapid product and process development with 100% controlled product quality. This technology is ideal for innovative biologic therapies such as gene therapy, RNA-based therapies, antibodies, vaccines, as well as precision medicine and orphan drug manufacturing.